Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Unveils Genomics Tool Employing DATAS

Premium

PARIS--ExonHit Therapeutics, the inventor of a gene profiling technology called Differential Analysis of Transcripts Alternatively Spliced, has introduced a predictive toxicology tool to enhance pharmaceutical and agrochemical research and development. Safe-Hit is a nucleic acid array that incorporates a library of genetic signaturesselected for being affected when cells and tissues are subjected to toxic stresses. A software module in the product reads the microarray, interprets results, and ranks compounds by toxicity.

According to the company, Safe-Hit works with alterations of transcripts, including gene splicing, obtained from a sustained expression of the wild-type p53 protein. The software is the first of a series of products based on the DATAS technology. Bruno Tocque, the company's CEO, said, "It is about time that genomics delivers in the field of toxicology, and Safe-Hit does just that." He called it a "complete product that will go a long way to taking the scientist's hunch out of lead molecule selection."

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.